The cost of surveillance for adenocarcinoma complicating Barrett's esophagus - PubMed (original) (raw)
Affiliations
- PMID: 3125739
The cost of surveillance for adenocarcinoma complicating Barrett's esophagus
E Achkar et al. Am J Gastroenterol. 1988 Mar.
Abstract
A review of endoscopic records at the Cleveland Clinic Foundation over a 7-yr period yielded 72 cases of Barrett's esophagus. Ten patients had adenocarcinoma at the time of diagnosis of Barrett's esophagus (14%). Sixty-two were followed for a mean of 31 months (range 2-154 months). During this follow-up period, cancer developed in one patient, an incidence of one cancer per 166 patient yr and an annual incidence of 0.6%. Males predominated in the group with both Barrett's esophagus (55 of 72) and adenocarcinoma (10 of 11). Symptoms were similar in those with simple Barrett's esophagus and those complicated by cancer. Our findings on incidence of cancer in Barrett's was applied to a model surveillance program. The cost of yearly endoscopic surveillance is estimated to be +62,000 and 78 lost work days to discover one cancer during the follow-up period. An endoscopic surveillance program requiring every-other-year studies appears justified and would cost only half as much, annually.
Similar articles
- Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
Provenzale D, Schmitt C, Wong JB. Provenzale D, et al. Am J Gastroenterol. 1999 Aug;94(8):2043-53. doi: 10.1111/j.1572-0241.1999.01276.x. Am J Gastroenterol. 1999. PMID: 10445526 - The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry.
O'Connor JB, Falk GW, Richter JE. O'Connor JB, et al. Am J Gastroenterol. 1999 Aug;94(8):2037-42. doi: 10.1111/j.1572-0241.1999.01275.x. Am J Gastroenterol. 1999. PMID: 10445525 - Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE. Sharma P, et al. Am J Gastroenterol. 1997 Nov;92(11):2012-6. Am J Gastroenterol. 1997. PMID: 9362182 - Barrett's esophagus surveillance: When, how often, does it work?
Katona BW, Falk GW. Katona BW, et al. Gastrointest Endosc Clin N Am. 2011 Jan;21(1):9-24. doi: 10.1016/j.giec.2010.09.003. Gastrointest Endosc Clin N Am. 2011. PMID: 21112494 Review. - Screening for Barrett's esophagus.
Spechler SJ. Spechler SJ. Rev Gastroenterol Disord. 2002;2 Suppl 2:S25-9. Rev Gastroenterol Disord. 2002. PMID: 12478241 Review.
Cited by
- Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.
Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Rabinovitch PS, et al. Am J Gastroenterol. 2001 Nov;96(11):3071-83. doi: 10.1111/j.1572-0241.2001.05261.x. Am J Gastroenterol. 2001. PMID: 11721752 Free PMC article. - Natural history of Barrett's esophagus.
Milind R, Attwood SE. Milind R, et al. World J Gastroenterol. 2012 Jul 21;18(27):3483-91. doi: 10.3748/wjg.v18.i27.3483. World J Gastroenterol. 2012. PMID: 22826612 Free PMC article. Review. - Value of DNA image cytometry in the prediction of malignant change in Barrett's oesophagus.
James PD, Atkinson M. James PD, et al. Gut. 1989 Jul;30(7):899-905. doi: 10.1136/gut.30.7.899. Gut. 1989. PMID: 2759487 Free PMC article. - Clinical implications of molecular changes in pediatric Barrett's esophagus.
Pensabene L, Cohen MC, Thomson M. Pensabene L, et al. Curr Gastroenterol Rep. 2012 Jun;14(3):253-61. doi: 10.1007/s11894-012-0252-x. Curr Gastroenterol Rep. 2012. PMID: 22373715 Review. - Barrett's oesophagus: a review of costs of the illness.
Arguedas MR, Eloubeidi MA. Arguedas MR, et al. Pharmacoeconomics. 2001;19(10):1003-11. doi: 10.2165/00019053-200119100-00003. Pharmacoeconomics. 2001. PMID: 11735670 Review.
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical